|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
Sep 2019 |
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
|
Genomics of myelodysplastic/myeloproliferative neoplasm |
May 2023 |
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Germline mutations in MDS/AML predisposition disorders |
Mar 2021 |
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
Oct 2023 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Germline variants in acquired aplastic anemia: current knowledge and future perspectives |
Sep 2024 |
Haematologica |
Aplastic Anemia |
|
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes |
Aug 2020 |
Cancer |
Myelodysplastic Syndromes (MDS) |
